This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Leo Qian, PhD
Co-Founder and Vice President, Discovery Research at Entrada Therapeutics


Ziqing “Leo” Qian, Ph.D. is co-founder and Vice President, Discovery Research at Entrada Therapeutics, a Boston-based biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular therapeutics. Dr. Qian co-invented Entrada’s Endosomal Escape Vehicle (EEV™) platform, which is applied to the design and development of intracellular delivery of otherwise impermeable biological cargos, including oligonucleotides, proteins, and peptides. Leo obtained his Ph.D. in Organic Chemistry from The Ohio State University. He has co-authored over 30 peer-reviewed publications and two book chapters, as well as co-inventor on over 10 patents.

Agenda Sessions

  • The Endosomal Escape Vehicle Platform of Cyclic Cell-Penetrating Peptides Enhances the Delivery of Oligonucleotides